Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation. Backed by Bessemer.
About the role
The Senior Director of Early Phase Formulation Development will provide scientific leadership for preformulation and early stage formulation activities across our portfolio of small molecule programs. This individual will serve as a hands-on scientific expert and team leader, driving enabling formulation strategies from candidate selection through early clinical development, with a focus on solving complex drug delivery and bioavailability challenges inherent to degrader molecules.
What they're looking for
- Ph.D. in Pharmaceutics, Pharmaceutical Sciences, Chemical Engineering, or related discipline with 15+ years of relevant pharmaceutical industry experience, with a focus on early-stage formulation development
- Demonstrated scientific expertise in early-stage pharmaceutical development, with a track record of advancing small molecule programs from discovery through IND and into clinical development
- Strong understanding of preformulation, biopharmaceutics, formulation development, and oral solid dose drug product manufacturing for small molecules
- Deep expertise in formulation approaches for poorly soluble compounds, including application of enabling technologies to improve bioavailability and product performance
- Proven track record of advancing small molecule programs through IND, with hands-on expertise in preformulation characterization, enabling formulation development, and early clinical drug product design
- Strong knowledge of GMP requirements, regulatory expectations, and evolving industry trends
More about this role
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn .
- PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
- COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
- BELONG : We recognize our differences, inviting...
Browse similar: Startup jobs